☰

Jeffrey A. Bluestone - Publications

Affiliations: 
University of Chicago, Chicago, IL 
Area:
Cell Biology, Immunology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

404 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Ho P, Cahir-McFarland E, Fontenot JD, Lodie T, Nada A, Tang Q, Turka LA, Bluestone JA. Harnessing regulatory T cells to establish immune tolerance. Science Translational Medicine. 16: eadm8859. PMID 38478632 DOI: 10.1126/scitranslmed.adm8859  0.41
2023 Bluestone JA, McKenzie BS, Beilke J, Ramsdell F. Opportunities for Treg cell therapy for the treatment of human disease. Frontiers in Immunology. 14: 1166135. PMID 37153574 DOI: 10.3389/fimmu.2023.1166135  0.458
2022 Goodman DB, Azimi CS, Kearns K, Talbot A, Garakani K, Garcia J, Patel N, Hwang B, Lee D, Park E, Vykunta VS, Shy BR, Ye CJ, Eyquem J, Marson A, ... Bluestone JA, et al. Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. Science Translational Medicine. 14: eabm1463. PMID 36350984 DOI: 10.1126/scitranslmed.abm1463  0.797
2022 VanDyke D, Iglesias M, Tomala J, Young A, Smith J, Perry JA, Gebara E, Cross AR, Cheung LS, Dykema AG, Orcutt-Jahns BT, Henclová T, Golias J, Balolong J, Tomasovic LM, ... ... Bluestone JA, et al. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Reports. 41: 111478. PMID 36261022 DOI: 10.1016/j.celrep.2022.111478  0.307
2022 Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J, Kornilov SA, Scherler K, Pavlovitch-Bedzyk AJ, Dong S, Lausted C, ... ... Bluestone JA, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. PMID 35216672 DOI: 10.1016/j.cell.2022.01.014  0.673
2021 Balcerek J, Shy BR, Putnam AL, Masiello LM, Lares A, Dekovic F, Acevedo L, Lee MR, Nguyen V, Liu W, Paruthiyil S, Xu J, Leinbach AS, Bluestone JA, Tang Q, et al. Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience. Frontiers in Immunology. 12: 744763. PMID 34867967 DOI: 10.3389/fimmu.2021.744763  0.558
2021 Muller YD, Ferreira LMR, Ronin E, Ho P, Nguyen V, Faleo G, Zhou Y, Lee K, Leung KK, Skartsis N, Kaul AM, Mulder A, Claas FHJ, Wells JA, Bluestone JA, et al. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Frontiers in Immunology. 12: 686439. PMID 34616392 DOI: 10.3389/fimmu.2021.686439  0.562
2021 Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, ... ... Bluestone JA, et al. The effects of low-dose IL-2 on Treg adoptive cell therapy in patients with Type 1 diabetes. Jci Insight. PMID 34324441 DOI: 10.1172/jci.insight.147474  0.591
2021 Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, Congrave-Wilson Z, Roth TL, Eyquem J, Van Gool F, Marson A, Perez L, Wells JA, Bluestone JA, Tang Q. The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. Frontiers in Immunology. 12: 639818. PMID 33833759 DOI: 10.3389/fimmu.2021.639818  0.739
2020 Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, Voillet V, Duvvuri VR, Scherler K, Troisch P, Baloni P, Qin G, Smith B, Kornilov SA, Rostomily C, ... ... Bluestone JA, et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. PMID 33171100 DOI: 10.1016/j.cell.2020.10.037  0.781
2020 Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Science Immunology. 5. PMID 33008914 DOI: 10.1126/sciimmunol.aba0759  0.301
2020 Bluestone JA, Tang Q. Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes. Cell Stem Cell. 27: 505-507. PMID 33007232 DOI: 10.1016/j.stem.2020.09.008  0.58
2020 Schumann K, Raju SS, Lauber M, Kolb S, Shifrut E, Cortez JT, Skartsis N, Nguyen VQ, Woo JM, Roth TL, Yu R, Nguyen MLT, Simeonov DR, Nguyen DN, Targ S, ... ... Bluestone JA, et al. Functional CRISPR dissection of gene networks controlling human regulatory T cell identity. Nature Immunology. PMID 32989329 DOI: 10.1038/s41590-020-0784-4  0.765
2020 Su Y, Chen D, Lausted C, Yuan D, Choi J, Dai C, Voillet V, Scherler K, Troisch P, Duvvuri VR, Baloni P, Qin G, Smith B, Kornilov S, Rostomily C, ... ... Bluestone JA, et al. Multiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories. Biorxiv : the Preprint Server For Biology. PMID 32766585 DOI: 10.1101/2020.07.27.224063  0.825
2020 Cortez JT, Montauti E, Shifrut E, Gatchalian J, Zhang Y, Shaked O, Xu Y, Roth TL, Simeonov DR, Zhang Y, Chen S, Li Z, Woo JM, Ho J, Vogel IA, ... ... Bluestone JA, et al. CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature. PMID 32499641 DOI: 10.1038/S41586-020-2246-4  0.714
2020 Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS, Tang Q, Guinan EC, Battaglia M, Burlingham WJ, Roberts ISD, Streitz M, Josien R, Böger CA, Scottà C, ... ... Bluestone JA, et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet (London, England). 395: 1627-1639. PMID 32446407 DOI: 10.1016/S0140-6736(20)30167-7  0.572
2020 Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, Yu R, Nguyen MLT, Lee Y, Truong A, Hiatt J, Wu D, Nguyen DN, Goodman D, Bluestone JA, et al. Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. Cell. PMID 32302591 DOI: 10.1016/J.Cell.2020.03.039  0.786
2020 Stewart MD, Keane A, Butterfield LH, Levine BL, Thompson B, Xu Y, Ramsborg C, Lee A, Kalos M, Koerner C, Moore T, Markovic I, Lasiter L, Ibrahim R, Bluestone J, et al. Accelerating the development of innovative cellular therapy products for the treatment of cancer. Cytotherapy. PMID 32199724 DOI: 10.1016/J.Jcyt.2020.01.014  0.327
2020 Mufazalov IA, Andruszewski D, Schelmbauer C, Heink S, Blanfeld M, Masri J, Tang Y, Schüler R, Eich C, Wunderlich FT, Karbach SH, Bluestone JA, Korn T, Waisman A. Cutting Edge: IL-6-Driven Immune Dysregulation Is Strictly Dependent on IL-6R α-Chain Expression. Journal of Immunology (Baltimore, Md. : 1950). PMID 31924653 DOI: 10.4049/Jimmunol.1900876  0.311
2019 Warshauer JT, Bluestone JA, Anderson MS. New Frontiers in the Treatment of Type 1 Diabetes. Cell Metabolism. PMID 31839487 DOI: 10.1016/J.Cmet.2019.11.017  0.368
2019 Nguyen DN, Roth TL, Li PJ, Chen PA, Apathy R, Mamedov MR, Vo LT, Tobin VR, Goodman D, Shifrut E, Bluestone JA, Puck JM, Szoka FC, Marson A. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nature Biotechnology. PMID 31819258 DOI: 10.1038/S41587-019-0325-6  0.812
2019 Raffin C, Vo LT, Bluestone JA. T cell-based therapies: challenges and perspectives. Nature Reviews. Immunology. PMID 31811270 DOI: 10.1038/S41577-019-0232-6  0.5
2019 Holohan DR, Van Gool F, Bluestone JA. Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model. Plos One. 14: e0217728. PMID 31647813 DOI: 10.1371/Journal.Pone.0217728  0.497
2019 Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nature Reviews. Drug Discovery. PMID 31541224 DOI: 10.1038/S41573-019-0041-4  0.711
2019 Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. The New England Journal of Medicine. PMID 31180194 DOI: 10.1056/Nejmoa1902226  0.34
2019 Azimi CS, Tang Q, Roybal KT, Bluestone JA. NextGen cell-based immunotherapies in cancer and other immune disorders. Current Opinion in Immunology. 59: 79-87. PMID 31071513 DOI: 10.1016/J.Coi.2019.03.007  0.655
2019 Van Gool F, Nguyen MLT, Mumbach MR, Satpathy AT, Rosenthal WL, Giacometti S, Le DT, Liu W, Brusko TM, Anderson MS, Rudensky AY, Marson A, Chang HY, Bluestone JA. A Mutation in the Transcription Factor Foxp3 Drives T Helper 2 Effector Function in Regulatory T Cells. Immunity. PMID 30709738 DOI: 10.1016/J.Immuni.2018.12.016  0.784
2019 DONG S, MOWERY CT, HEROLD KC, GITELMAN SE, ESENSTEN JH, LIU W, LARES AP, LEINBACH AS, LEE MR, NGUYEN VQ, PUTNAM AL, YE J, TANG Q, BLUESTONE J. 253-LB: Effect of Combined Low Dose IL-2 plus Polyclonal Tregs in Type 1 Diabetes Patients Diabetes. 68: 253-LB. DOI: 10.2337/Db19-253-Lb  0.666
2019 Young A, Nguyen V, Kang JH, Mehdizadeh S, Mei A, Sheehan KCF, Serreze DV, Chen Y, Schreiber RD, Bluestone JA. Abstract PR07: Developing syngeneic NOD tumor models to profile immunotoxicity and antitumor immunity in response to cancer immunotherapies in autoimmune-prone mice Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr07  0.362
2018 Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Frontiers in Medicine. 5: 351. PMID 30631766 DOI: 10.3389/Fmed.2018.00351  0.313
2018 Young A, Quandt Z, Bluestone JA. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunology Research. 6: 1445-1452. PMID 30510057 DOI: 10.1158/2326-6066.Cir-18-0487  0.323
2018 Bucktrout SL, Bluestone JA, Ramsdell F. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Medicine. 10: 79. PMID 30376867 DOI: 10.1186/S13073-018-0588-4  0.381
2018 Esensten JH, Muller YD, Bluestone JA, Tang Q. Regulatory T cell therapy for autoimmune and autoinflammatory diseases: the next frontier. The Journal of Allergy and Clinical Immunology. PMID 30367909 DOI: 10.1016/J.Jaci.2018.10.015  0.655
2018 Bluestone JA, Tang Q. T cells-the next frontier of cell therapy. Science (New York, N.Y.). 362: 154-155. PMID 30309932 DOI: 10.1126/Science.Aau2688  0.676
2018 Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandoval PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, et al. Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus. Arthritis & Rheumatology (Hoboken, N.J.). PMID 30277008 DOI: 10.1002/Art.40737  0.671
2018 Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC. Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. Journal of Immunology (Baltimore, Md. : 1950). PMID 30104245 DOI: 10.4049/Jimmunol.1800578  0.347
2018 Bluestone JA. Chance favours the prepared mind. Nature Reviews. Immunology. PMID 30018454 DOI: 10.1038/S41577-018-0043-1  0.475
2018 Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA. Revisiting IL-2: Biology and therapeutic prospects. Science Immunology. 3. PMID 29980618 DOI: 10.1126/Sciimmunol.Aat1482  0.722
2018 Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, Holst CR, Coyle A, Potempa M, Lanier LL, Garcia KC, Crellin NK, Rondon IJ, Bluestone JA. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nature Medicine. PMID 29942088 DOI: 10.1038/S41591-018-0070-2  0.415
2018 Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, ... ... Bluestone JA, et al. Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature. PMID 29899441 DOI: 10.1038/S41586-018-0227-7  0.649
2018 Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M. Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Reports. 23: 3262-3274. PMID 29898397 DOI: 10.1016/J.Celrep.2018.05.050  0.428
2018 Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M. Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges. Cell Stem Cell. 22: 810-823. PMID 29859172 DOI: 10.1016/J.Stem.2018.05.016  0.619
2018 Spence A, Purtha W, Tam J, Dong S, Kim Y, Ju C, Sterling T, Nakayama M, Robinson WH, Bluestone JA, Anderson MS, Tang Q. Correction for Spence et al., Revealing the specificity of regulatory T cells in murine autoimmune diabetes. Proceedings of the National Academy of Sciences of the United States of America. 115. PMID 29844176 DOI: 10.1073/Pnas.1808331115  0.619
2018 Hua J, Inomata T, Chen Y, Foulsham W, Stevenson W, Shiang T, Bluestone JA, Dana R. Pathological conversion of regulatory T cells is associated with loss of allotolerance. Scientific Reports. 8: 7059. PMID 29728574 DOI: 10.1038/S41598-018-25384-X  0.485
2018 Spence A, Purtha W, Tam J, Dong S, Kim Y, Ju CH, Sterling T, Nakayama M, Robinson WH, Bluestone JA, Anderson MS, Tang Q. Revealing the specificity of regulatory T cells in murine autoimmune diabetes. Proceedings of the National Academy of Sciences of the United States of America. PMID 29712852 DOI: 10.1073/Pnas.1715590115  0.7
2018 Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, ... ... Bluestone JA, et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science (New York, N.Y.). 359: 1037-1042. PMID 29496879 DOI: 10.1126/Science.Aar3246  0.427
2017 Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, et al. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology. 8: 1844. PMID 29379498 DOI: 10.3389/Fimmu.2017.01844  0.768
2017 Yeh WI, Seay HR, Newby B, Posgai AL, Moniz FB, Michels A, Mathews CE, Bluestone JA, Brusko TM. Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes. Frontiers in Immunology. 8: 1313. PMID 29123516 DOI: 10.3389/Fimmu.2017.01313  0.713
2017 Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, ... ... Bluestone JA, et al. Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature. PMID 28854172 DOI: 10.1038/Nature23875  0.673
2017 Chandran S, Tang Q, Sarwal M, Laszik ZG, Putnam AL, Lee K, Leung J, Nguyen V, Sigdel T, Tavares EC, Yang JYC, Hellerstein M, Fitch M, Bluestone JA, Vincenti F. Polyclonal Regulatory T cell Therapy for Control of Inflammation in Kidney Transplants. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 28675676 DOI: 10.1111/Ajt.14415  0.628
2017 Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR. Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes. Cell Metabolism. 25: 1207. PMID 28467938 DOI: 10.1016/J.Cmet.2017.04.026  0.389
2017 Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR. Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes. Cell Metabolism. 25: 883-897.e8. PMID 28380378 DOI: 10.1016/J.Cmet.2017.03.018  0.319
2017 Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters LD, Bushdorf AN, Atkinson MA, ... Bluestone JA, et al. Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Molecular Therapy. Methods & Clinical Development. 4: 178-191. PMID 28345003 DOI: 10.1016/J.Omtm.2016.12.003  0.728
2017 Bluestone JA. FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance. Journal of Immunology (Baltimore, Md. : 1950). 198: 979-980. PMID 28115585 DOI: 10.4049/Jimmunol.1602060  0.464
2017 Lee JC, Tsai KK, Algazi AP, Rosenblum M, Bluestone J, Daud A. Relationship between liver metastases and PD-1 blockade in melanoma. Journal of Clinical Oncology. 35: 3072-3072. DOI: 10.1200/Jco.2017.35.15_Suppl.3072  0.364
2017 Wang DQ, Quiros JR, Pai CS, Fong LH, Bluestone JA, DuPage MJ. Abstract 1014: Selective impairment of intratumoral regulatory T cells by targeting Ezh2 enhances cancer immunity Immunology. 77: 1014-1014. DOI: 10.1158/1538-7445.Am2017-1014  0.431
2016 Esensten JH, Bluestone JA, Lim WA. Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annual Review of Pathology. PMID 27959633 DOI: 10.1146/Annurev-Pathol-052016-100304  0.46
2016 Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 Costimulation: From Mechanism to Therapy. Immunity. 44: 973-88. PMID 27192564 DOI: 10.1016/J.Immuni.2016.04.020  0.699
2016 Gitelman SE, Bluestone JA. Regulatory T cell therapy for type 1 diabetes: May the force be with you. Journal of Autoimmunity. 71: 78-87. PMID 27133597 DOI: 10.1016/J.Jaut.2016.03.011  0.55
2016 Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, et al. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia. PMID 27053235 DOI: 10.1007/S00125-016-3917-4  0.363
2016 DuPage M, Bluestone JA. Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nature Reviews. Immunology. 16: 149-63. PMID 26875830 DOI: 10.1038/Nri.2015.18  0.555
2016 Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF. CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. Journal of Immunology (Baltimore, Md. : 1950). PMID 26826243 DOI: 10.4049/Jimmunol.1501491  0.437
2015 Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC. Inducing and Administering Tregs to Treat Human Disease. Frontiers in Immunology. 6: 654. PMID 26834735 DOI: 10.3389/Fimmu.2015.00654  0.5
2015 Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science Translational Medicine. 7: 315ra189. PMID 26606968 DOI: 10.1126/Scitranslmed.Aad4134  0.716
2015 Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Molecular Genetics and Metabolism. PMID 26597321 DOI: 10.1016/J.Ymgme.2015.11.001  0.326
2015 Holohan DR, Lee JC, Bluestone JA. Shifting the Evolving CAR T Cell Platform into Higher Gear. Cancer Cell. 28: 401-2. PMID 26461084 DOI: 10.1016/J.Ccell.2015.09.014  0.532
2015 Spence A, Klementowicz JE, Bluestone JA, Tang Q. Targeting Treg signaling for the treatment of autoimmune diseases. Current Opinion in Immunology. 37: 11-20. PMID 26432763 DOI: 10.1016/J.Coi.2015.09.002  0.645
2015 Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, Marson A. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proceedings of the National Academy of Sciences of the United States of America. 112: 10437-42. PMID 26216948 DOI: 10.1073/Pnas.1512503112  0.703
2015 Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM. Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. Immunity. 43: 161-74. PMID 26092469 DOI: 10.1016/J.Immuni.2015.05.019  0.375
2015 Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, ... ... Bluestone JA, et al. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. Journal of Immunology (Baltimore, Md. : 1950). 195: 145-55. PMID 25994968 DOI: 10.4049/Jimmunol.1402381  0.814
2015 Bluestone JA, Bour-Jordan H, Cheng M, Anderson M. T cells in the control of organ-specific autoimmunity. The Journal of Clinical Investigation. 125: 2250-60. PMID 25985270 DOI: 10.1172/Jci78089  0.435
2015 Bluestone JA, Trotta E, Xu D. The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opinion On Therapeutic Targets. 19: 1091-103. PMID 25881491 DOI: 10.1517/14728222.2015.1037282  0.499
2015 Bluestone JA, Tang Q. Immunotherapy: making the case for precision medicine. Science Translational Medicine. 7: 280ed3. PMID 25810308 DOI: 10.1126/Scitranslmed.Aaa9846  0.524
2015 DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone JA. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity. 42: 227-38. PMID 25680271 DOI: 10.1016/J.Immuni.2015.01.007  0.803
2015 Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, Townamchai N, Gerriets VA, Rathmell JC, Sharpe AH, Bluestone JA, Turka LA. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nature Immunology. 16: 188-96. PMID 25559257 DOI: 10.1038/Ni.3077  0.53
2015 Szot GL, Yadav M, Lang J, Kroon E, Kerr J, Kadoya K, Brandon EP, Baetge EE, Bour-Jordan H, Bluestone JA. Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell. 16: 148-57. PMID 25533131 DOI: 10.1016/J.Stem.2014.12.001  0.782
2015 Fuhrman CA, Yeh WI, Seay HR, Lakshmi PS, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, Von Schack D, ... ... Bluestone JA, et al. Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226 Journal of Immunology. 195: 145-155. DOI: 10.4049/jimmunol.1402381  0.76
2015 Vincenti F, Tang Q, Laszik Z, Sarwal M, Bluestone J, Chandran S. FP886T REGULATORY CELL THERAPY TO CONTROL INFLAMMATION IN RENAL ALLOGRAFTS Nephrology Dialysis Transplantation. 30: iii372-iii373. DOI: 10.1093/Ndt/Gfv185.75  0.572
2014 Xu P, Bailey-Bucktrout S, Xi Y, Xu D, Du D, Zhang Q, Xiang W, Liu J, Melton A, Sheppard D, Chapman HA, Bluestone JA, Derynck R. Innate antiviral host defense attenuates TGF-β function through IRF3-mediated suppression of Smad signaling. Molecular Cell. 56: 723-37. PMID 25526531 DOI: 10.1016/J.Molcel.2014.11.027  0.343
2014 Van Gool F, Molofsky AB, Morar MM, Rosenzwajg M, Liang HE, Klatzmann D, Locksley RM, Bluestone JA. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood. 124: 3572-6. PMID 25323825 DOI: 10.1182/Blood-2014-07-587493  0.317
2014 Villalta SA, Rosenthal W, Martinez L, Kaur A, Sparwasser T, Tidball JG, Margeta M, Spencer MJ, Bluestone JA. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Science Translational Medicine. 6: 258ra142. PMID 25320234 DOI: 10.1126/Scitranslmed.3009925  0.314
2014 Folias AE, Penaranda C, Su AL, Bluestone JA, Hebrok M. Aberrant innate immune activation following tissue injury impairs pancreatic regeneration. Plos One. 9: e102125. PMID 25010227 DOI: 10.1371/Journal.Pone.0102125  0.767
2014 Stumpf M, Zhou X, Chikuma S, Bluestone JA. Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. European Journal of Immunology. 44: 1737-46. PMID 24648182 DOI: 10.1002/Eji.201343891  0.558
2014 Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nature Medicine. 20: 62-8. PMID 24362934 DOI: 10.1038/Nm.3432  0.557
2014 Putnam A, Lares A, Liu W, Lee M, Gitelman S, Herold K, Warner N, Bluestone J. Results following completion of phase I clinical trial using ex vivo expanded CD4+CD127lo/-CD25+ polyclonal tregs for the treatment of recent-onset type 1 diabetes Cytotherapy. 16: S7. DOI: 10.1016/J.Jcyt.2014.01.013  0.374
2014 Guleria I, Bupp MG, Dada S, Fife BT, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH. Corrigendum to 'Mechanisms of PDL1-mediated regulation of autoimmune diabetes' [Clin. Immunol. 125 (2007) 16-25] Clinical Immunology. 150: 134. DOI: 10.1016/J.Clim.2013.09.004  0.746
2013 Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, ... Bluestone JA, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. The Lancet. Diabetes & Endocrinology. 1: 306-16. PMID 24622416 DOI: 10.1089/Dia.2014.1510  0.373
2013 Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity. 39: 949-62. PMID 24238343 DOI: 10.1016/J.Immuni.2013.10.016  0.538
2013 Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harbor Perspectives in Medicine. 3. PMID 24186492 DOI: 10.1101/Cshperspect.A015552  0.626
2013 Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, Trotta E, Szot GL, Liu W, Lares A, Lee K, Laing A, Lechler RI, Riley JL, Bluestone JA, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 13: 3010-20. PMID 24102808 DOI: 10.1111/Ajt.12433  0.67
2013 Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Frontiers in Immunology. 4: 232. PMID 23966994 DOI: 10.3389/Fimmu.2013.00232  0.523
2013 Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. The Journal of Experimental Medicine. 210: 1603-19. PMID 23878307 DOI: 10.1084/Jem.20122387  0.55
2013 Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone JA, Fischbach MA. Production of α-galactosylceramide by a prominent member of the human gut microbiota. Plos Biology. 11: e1001610. PMID 23874157 DOI: 10.1371/Journal.Pbio.1001610  0.763
2013 de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 191: 1594-605. PMID 23858035 DOI: 10.4049/Jimmunol.1203567  0.35
2013 Bour-Jordan H, Thompson HL, Giampaolo JR, Davini D, Rosenthal W, Bluestone JA. Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background. Journal of Autoimmunity. 45: 58-67. PMID 23850635 DOI: 10.1016/J.Jaut.2013.06.005  0.345
2013 Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA. Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes. 62: 2870-8. PMID 23835340 DOI: 10.2337/Db12-1619  0.54
2013 Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 62: 3766-74. PMID 23835333 DOI: 10.1089/Dia.2014.1510  0.337
2013 Baumjohann D, Kageyama R, Clingan JM, Morar MM, Patel S, de Kouchkovsky D, Bannard O, Bluestone JA, Matloubian M, Ansel KM, Jeker LT. The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nature Immunology. 14: 840-8. PMID 23812098 DOI: 10.1038/Ni.2642  0.393
2013 Jeker LT, Zhou X, Blelloch R, Bluestone JA. DGCR8-mediated production of canonical microRNAs is critical for regulatory T cell function and stability. Plos One. 8: e66282. PMID 23741528 DOI: 10.1371/Journal.Pone.0066282  0.393
2013 Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Science Translational Medicine. 5: 179ps7. PMID 23552369 DOI: 10.1126/Scitranslmed.3005568  0.308
2013 Jeker LT, Bluestone JA. MicroRNA regulation of T-cell differentiation and function. Immunological Reviews. 253: 65-81. PMID 23550639 DOI: 10.1111/Imr.12061  0.328
2013 Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, Riley JL, Ziegler SF. Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28. Journal of Immunology (Baltimore, Md. : 1950). 190: 4470-3. PMID 23543754 DOI: 10.4049/Jimmunol.1203561  0.398
2013 Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nature Reviews. Immunology. 13: 243-56. PMID 23524461 DOI: 10.1038/Nri3422  0.303
2013 Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF. Regulatory T cells: recommendations to simplify the nomenclature. Nature Immunology. 14: 307-8. PMID 23507634 DOI: 10.1038/Ni.2554  0.516
2013 Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC. Immune therapy and β-cell death in type 1 diabetes. Diabetes. 62: 1676-80. PMID 23423576 DOI: 10.2337/Db12-1207  0.365
2013 Stumpf M, Zhou X, Bluestone JA. The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. Journal of Immunology (Baltimore, Md. : 1950). 190: 961-9. PMID 23293354 DOI: 10.4049/Jimmunol.1201362  0.52
2013 Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 56: 391-400. PMID 23086558 DOI: 10.1007/S00125-012-2753-4  0.326
2013 Bluestone JA, Bailey-Bucktrout S, Xu P, Derynck R, Trotta E, Crellins N, Rondon I, DuPage M, Travis M, Sheppard D. S-1 Cytokine. 63: 241. DOI: 10.1016/J.Cyto.2013.06.302  0.38
2013 Baumjohann D, Kageyama R, Clingan JM, Morar MM, Patel S, de Kouchkovsky D, Bannard O, Bluestone JA, Matloubian M, Ansel KM, Jeker LT. 16 Cytokine. 63: 246-247. DOI: 10.1016/J.Cyto.2013.06.019  0.442
2012 Bluestone JA, Bour-Jordan H. Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harbor Perspectives in Biology. 4. PMID 23125012 DOI: 10.1101/Cshperspect.A007542  0.473
2012 Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transplant International : Official Journal of the European Society For Organ Transplantation. 25: 1257-67. PMID 22994802 DOI: 10.1111/J.1432-2277.2012.01565.X  0.724
2012 Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Von Schack D, Bluestone JA. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. The Journal of Experimental Medicine. 209: 1713-22, S1-19. PMID 22966003 DOI: 10.1084/Jem.20120822  0.56
2012 Bluestone JA, Small EJ. The future of cancer treatment: will it include immunotherapy? Cancer Cell. 22: 7-8. PMID 22789534 DOI: 10.1016/J.Ccr.2012.06.009  0.342
2012 Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KM. Single step isolation and activation of primary CD3 + T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers Nano Letters. 12: 4018-4024. PMID 22784189 DOI: 10.1021/Nl301388D  0.455
2012 Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran P, Walker LS, Bluestone JA, Abbas AK, Dooms H. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proceedings of the National Academy of Sciences of the United States of America. 109: 12668-73. PMID 22733744 DOI: 10.1073/Pnas.1203692109  0.812
2012 Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, ... Bluestone JA, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 61: 2340-8. PMID 22721971 DOI: 10.1089/Dia.2013.1510  0.389
2012 Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar MM, Stadthagen G, Lund AH, Bluestone JA. MicroRNA 10a marks regulatory T cells. Plos One. 7: e36684. PMID 22629323 DOI: 10.1371/Journal.Pone.0036684  0.323
2012 Beilke JN, Meagher CT, Hosiawa K, Champsaur M, Bluestone JA, Lanier LL. NK cells are not required for spontaneous autoimmune diabetes in NOD mice. Plos One. 7: e36011. PMID 22558306 DOI: 10.1371/Journal.Pone.0036011  0.455
2012 Jeker LT, Bour-Jordan H, Bluestone JA. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harbor Perspectives in Medicine. 2: a007807. PMID 22393537 DOI: 10.1101/Cshperspect.A007807  0.432
2012 Tang Q, Bluestone JA, Kang SM. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. Journal of Molecular Cell Biology. 4: 11-21. PMID 22170955 DOI: 10.1093/Jmcb/Mjr047  0.692
2012 Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. How does type 1 diabetes develop? The notion of homicide or β-cell suicide revisited (Diabetes (2011) 60, (1370-1379)) Diabetes. 61: 1648. DOI: 10.2337/Db12-Er06A  0.511
2011 Tada A, Shimada A, Yamada T, Oikawa Y, Yamada Y, Okubo Y, Irie J, Bluestone JA, Itoh H. A mimic of viral double-stranded RNA triggers fulminant type 1 diabetes-like syndrome in regulatory T cell-deficient autoimmune diabetic mouse. Journal of Immunology (Baltimore, Md. : 1950). 187: 4947-53. PMID 21967896 DOI: 10.4049/Jimmunol.1000837  0.478
2011 Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413. Journal of Immunology (Baltimore, Md. : 1950). 187: 3466-74. PMID 21934098  0.364
2011 Beyer M, Thabet Y, Müller RU, Sadlon T, Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, Schönfeld EA, Böttcher J, Golovina T, Mayer CT, Hofmann A, ... ... Bluestone JA, et al. Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nature Immunology. 12: 898-907. PMID 21841785 DOI: 10.1038/Ni.2084  0.513
2011 Herold KC, Bluestone JA. Type 1 diabetes immunotherapy: is the glass half empty or half full? Science Translational Medicine. 3: 95fs1. PMID 21832236 DOI: 10.1126/Scitranslmed.3002981  0.311
2011 Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O'Connor W, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, et al. Control of TH17 cells occurs in the small intestine. Nature. 475: 514-8. PMID 21765430 DOI: 10.1038/Nature10228  0.505
2011 Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. Journal of Immunology (Baltimore, Md. : 1950). 187: 2015-22. PMID 21742976 DOI: 10.4049/Jimmunol.1100713  0.845
2011 Bailey-Bucktrout SL, Bluestone JA. Regulatory T cells: stability revisited. Trends in Immunology. 32: 301-6. PMID 21620768 DOI: 10.1016/J.It.2011.04.002  0.51
2011 Rainbow DB, Moule C, Fraser HI, Clark J, Howlett SK, Burren O, Christensen M, Moody V, Steward CA, Mohammed JP, Fusakio ME, Masteller EL, Finger EB, Houchins JP, Naf D, ... ... Bluestone JA, et al. Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice. Journal of Immunology (Baltimore, Md. : 1950). 187: 325-36. PMID 21613616 DOI: 10.4049/Jimmunol.1003523  0.499
2011 Brennan TV, Tang Q, Liu FC, Hoang V, Bi M, Bluestone JA, Kang SM. Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts. The Journal of Surgical Research. 169: e69-75. PMID 21571317 DOI: 10.1016/J.Jss.2011.03.021  0.718
2011 Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, Rhodes CJ. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes. 60: 1370-9. PMID 21525508 DOI: 10.2337/Db10-1797  0.533
2011 Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunological Reviews. 241: 180-205. PMID 21488898 DOI: 10.1111/J.1600-065X.2011.01011.X  0.835
2011 McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. Journal of Immunology (Baltimore, Md. : 1950). 186: 3918-26. PMID 21368230 DOI: 10.4049/Jimmunol.1003099  0.687
2011 Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller EL, Bluestone JA, Singh B. Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. Journal of Immunology (Baltimore, Md. : 1950). 186: 3831-5. PMID 21357258 DOI: 10.4049/Jimmunol.1003617  0.481
2011 Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. Plos One. 6: e15868. PMID 21253593 DOI: 10.1371/Journal.Pone.0015868  0.698
2010 Melton AC, Bailey-Bucktrout SL, Travis MA, Fife BT, Bluestone JA, Sheppard D. Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. The Journal of Clinical Investigation. 120: 4436-44. PMID 21099117 DOI: 10.1172/Jci43786  0.718
2010 Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 90: 1595-601. PMID 20978464 DOI: 10.1097/Tp.0B013E3181Fe1377  0.363
2010 Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA. The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nature Reviews. Immunology. 10: 797-803. PMID 20972473 DOI: 10.1038/Nri2869  0.33
2010 Sonn CH, Yu YB, Hong YJ, Shim YJ, Bluestone JA, Min BH, Lee KM. Clusterin synergizes with IL-2 for the expansion and IFN-γ production of natural killer cells. Journal of Leukocyte Biology. 88: 955-63. PMID 20729304 DOI: 10.1189/Jlb.0310157  0.422
2010 Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. The Journal of Experimental Medicine. 207: 1871-8. PMID 20679400 DOI: 10.1084/Jem.20100209  0.713
2010 Kim TJ, Kim N, Kang HJ, Kim EO, Kim ST, Ahn HS, Bluestone JA, Lee KM. FK506 causes cellular and functional defects in human natural killer cells. Journal of Leukocyte Biology. 88: 1089-97. PMID 20671192 DOI: 10.1189/Jlb.0310148  0.466
2010 Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. Plos One. 5: e11726. PMID 20668510 DOI: 10.1371/Journal.Pone.0011726  0.761
2010 Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 10: 1870-80. PMID 20659093 DOI: 10.1111/J.1600-6143.2010.03073.X  0.301
2010 Shoda L, Kreuwel H, Gadkar K, Zheng Y, Whiting C, Atkinson M, Bluestone J, Mathis D, Young D, Ramanujan S. The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clinical and Experimental Immunology. 161: 250-67. PMID 20491795 DOI: 10.1111/J.1365-2249.2010.04166.X  0.569
2010 Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 464: 1293-300. PMID 20432533 DOI: 10.1038/Nature08933  0.357
2010 Kim TJ, Kim N, Kim EO, Choi JR, Bluestone JA, Lee KM. Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor. Immunology. 130: 545-55. PMID 20406306 DOI: 10.1111/J.1365-2567.2010.03253.X  0.431
2010 Jeker LT, Bluestone JA. Small RNA regulators of T cell-mediated autoimmunity. Journal of Clinical Immunology. 30: 347-57. PMID 20393792 DOI: 10.1007/S10875-010-9392-7  0.307
2010 Penaranda C, Tang Q, Ruddle NH, Bluestone JA. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes. 59: 1461-8. PMID 20299465 DOI: 10.2337/Db09-1129  0.793
2010 Posselt AM, Szot G, Frassetto L, Masharani U, Tavakol M, Vincenti F, Fong L, Bluestone J, Stock P. ISLET ALLOGRAFT SURVIVAL IN TYPE 1 DIABETIC PATIENTS USING CALCINEURIN INHIBITOR-FREE PROTOCOLS BASED ON T-CELL ADHESION OR COSTIMULATION BLOCKADE Transplantation Journal. 90: 134. DOI: 10.1097/00007890-201007272-00258  0.412
2010 Brusko T, Koya R, Zhu S, Lee M, Putnam A, McClymont S, Nishimura M, Xia N, Bluestone J. Lentiviral TCR-engineered Tregs Demonstrate Effective Suppression of T Cell Responses Clinical Immunology. 135: S30. DOI: 10.1016/J.Clim.2010.03.093  0.672
2010 Putnam A, Lee M, Liu W, Escosa H, Brusko T, Bluestone J. The Use of CD4+CD127lo/-CD25+ Polyclonal Tregs for the Treatment of Recent Onset T1D in a Phase I Clinical Trial Clinical Immunology. 135: S23. DOI: 10.1016/J.Clim.2010.03.073  0.614
2010 McClymont S, Putnam A, Lee M, Esensten J, Liu W, Olek S, Baron U, Hoffmuller U, Bluestone J, Brusko T. Plasticity of Human Regulatory T Cells - Characterization of IFN-γ-Producing Cells Clinical Immunology. 135: S5-S6. DOI: 10.1016/J.Clim.2010.03.023  0.686
2009 Brusko TM, Bluestone JA. Regulatory T cells directed to the site of the action. Proceedings of the National Academy of Sciences of the United States of America. 106: 20553-4. PMID 19955436 DOI: 10.1073/Pnas.0911848107  0.674
2009 Penaranda C, Bluestone JA. Is antigen specificity of autoreactive T cells the key to islet entry? Immunity. 31: 534-6. PMID 19833083 DOI: 10.1016/J.Immuni.2009.09.006  0.805
2009 Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nature Reviews. Immunology. 9: 811-6. PMID 19809471 DOI: 10.1038/Nri2654  0.493
2009 Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nature Reviews. Rheumatology. 5: 560-5. PMID 19798031 DOI: 10.1038/Nrrheum.2009.183  0.457
2009 Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nature Immunology. 10: 1185-92. PMID 19783989 DOI: 10.1038/Ni.1790  0.81
2009 Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martínez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nature Immunology. 10: 1000-7. PMID 19633673 DOI: 10.1038/Ni.1774  0.831
2009 Norquay LD, D'Aquino KE, Opare-Addo LM, Kuznetsova A, Haas M, Bluestone JA, White MF. Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice. Endocrinology. 150: 4531-40. PMID 19574401 DOI: 10.1210/En.2009-0395  0.373
2009 Perruche S, Zhang P, Maruyama T, Bluestone JA, Saas P, Chen W. Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome. Journal of Immunology (Baltimore, Md. : 1950). 183: 953-61. PMID 19561097 DOI: 10.4049/Jimmunol.0804076  0.397
2009 Esensten JH, Lee MR, Glimcher LH, Bluestone JA. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. Journal of Immunology (Baltimore, Md. : 1950). 183: 75-82. PMID 19535634 DOI: 10.4049/Jimmunol.0804154  0.554
2009 Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, Mellor A, Bluestone JA, Moser M. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut. 58: 1363-73. PMID 19505881 DOI: 10.1136/Gut.2008.162842  0.518
2009 Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Current Opinion in Immunology. 21: 281-5. PMID 19500966 DOI: 10.1016/J.Coi.2009.05.007  0.551
2009 Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clinical Immunology (Orlando, Fla.). 132: 166-73. PMID 19443276 DOI: 10.1016/J.Clim.2009.04.007  0.433
2009 Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunological Reviews. 229: 41-66. PMID 19426214 DOI: 10.1111/J.1600-065X.2009.00775.X  0.548
2009 Louvet C, Kabre BG, Davini DW, Martinier N, Su MA, DeVoss JJ, Rosenthal WL, Anderson MS, Bour-Jordan H, Bluestone JA. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. The Journal of Experimental Medicine. 206: 507-14. PMID 19221395 DOI: 10.1084/Jem.20082113  0.545
2009 Su MA, Stenerson M, Liu W, Putnam A, Conte F, Bluestone JA, Anderson MS. The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients. Clinical Immunology (Orlando, Fla.). 131: 139-44. PMID 19150256 DOI: 10.1016/J.Clim.2008.11.007  0.492
2009 Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 58: 652-62. PMID 19074986 DOI: 10.2337/Db08-1168  0.747
2009 Putnam A, McClymont S, Brusko T, Lee M, Liu W, Ghosh T, Bluestone J. T.115. Stability and Purity of Expanded Human CD4+CD127lo/-CD25+Tregs for Use in Cellular Therapy for the Treatment of Type 1 Diabetes Clinical Immunology. 131: S84-S85. DOI: 10.1016/J.Clim.2009.03.248  0.668
2009 Brusko T, Zhu S, Putnam A, Lee M, McClymont S, Liu W, Nishimura M, Koya R, Tree T, Riley J, Bluestone J. OR.105. Development of Engineered Antigen-specific Human Regulatory T Cells for the Treatment of Type 1 Diabetes by TCR Gene Transfer Clinical Immunology. 131: S42-S43. DOI: 10.1016/J.Clim.2009.03.120  0.655
2008 You S, Alyanakian M, Segovia B, Damotte D, Bluestone J, Bach J, Chatenoud L. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Annals of the New York Academy of Sciences. 1150: 300-310. PMID 19120317 DOI: 10.1196/Annals.1447.046  0.52
2008 Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proceedings of the National Academy of Sciences of the United States of America. 105: 18895-900. PMID 19015530 DOI: 10.1073/Pnas.0810246105  0.322
2008 Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation American Journal of Transplantation. 8: 2086-2096. PMID 18828769 DOI: 10.1111/J.1600-6143.2008.02377.X  0.513
2008 Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 455: 1109-13. PMID 18806780 DOI: 10.1038/Nature07336  0.391
2008 Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunological Reviews. 224: 166-82. PMID 18759926 DOI: 10.1111/J.1600-065X.2008.00662.X  0.699
2008 Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. The Journal of Experimental Medicine. 205: 1983-91. PMID 18725525 DOI: 10.1084/Jem.20080707  0.757
2008 Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. Journal of Clinical Immunology. 28: 677-84. PMID 18716861 DOI: 10.1007/S10875-008-9242-Z  0.641
2008 Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 57: 3013-24. PMID 18689692 DOI: 10.2337/Db08-0420  0.493
2008 Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunological Reviews. 223: 371-90. PMID 18613848 DOI: 10.1111/J.1600-065X.2008.00637.X  0.667
2008 Meagher C, Tang Q, Fife BT, Bour-Jordan H, Wu J, Pardoux C, Bi M, Melli K, Bluestone JA. Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. Journal of Immunology (Baltimore, Md. : 1950). 180: 7793-803. PMID 18523243 DOI: 10.4049/Jimmunol.180.12.7793  0.817
2008 Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA. Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction Immunity. 28: 687-697. PMID 18468463 DOI: 10.1016/J.Immuni.2008.03.016  0.844
2008 Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specific antibody–induced immune tolerance involves transforming growth factor-β from phagocytes digesting apoptotic T cells Nature Medicine. 14: 528-535. PMID 18438416 DOI: 10.1038/Nm1749  0.524
2008 Brusko T, Bluestone J. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. European Journal of Immunology. 38: 931-4. PMID 18395864 DOI: 10.1002/Eji.200738108  0.677
2008 Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: A jack of all trades, master of regulation Nature Immunology. 9: 239-244. PMID 18285775 DOI: 10.1038/Ni1572  0.704
2008 Bluestone JA, Hebrok M. Safer, longer-lasting regulatory T cells with beta-catenin. Nature Medicine. 14: 118-9. PMID 18256611 DOI: 10.1038/Nm0208-118  0.436
2008 Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, Evan GI, Bluestone JA, Hebrok M. Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes. 57: 958-66. PMID 18083786 DOI: 10.2337/Db07-0913  0.754
2008 Tang Q, Walker LS, Bluestone JA. Response: Regulating Treg Cells at Sites of Inflammation Immunity. 29: 512. DOI: 10.1016/J.Immuni.2008.09.011  0.656
2007 Szot GL, Koudria P, Bluestone JA. Transplantation of pancreatic islets into the kidney capsule of diabetic mice. Journal of Visualized Experiments : Jove. 404. PMID 18989445 DOI: 10.3791/404  0.363
2007 Bour-Jordan H, Bluestone JA. B cell depletion: a novel therapy for autoimmune diabetes? Journal of Clinical Investigation. 117: 3642-3645. PMID 18060022 DOI: 10.1172/Jci34236  0.466
2007 Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA, Sheppard D. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature. 449: 361-5. PMID 17694047 DOI: 10.1038/Nature06110  0.551
2007 Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology. 148: 5136-44. PMID 17673522 DOI: 10.1210/En.2007-0358  0.65
2007 Bluestone JA, Thomson AW, Shevach EM, Weiner HL. What does the future hold for cell-based tolerogenic therapy? Nature Reviews. Immunology. 7: 650-4. PMID 17653127 DOI: 10.1038/Nri2137  0.489
2007 Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nature Reviews. Immunology. 7: 622-32. PMID 17641665 DOI: 10.1038/Nri2134  0.524
2007 Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clinical Immunology (Orlando, Fla.). 125: 16-25. PMID 17627890 DOI: 10.1016/J.Clim.2007.05.013  0.828
2007 Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, Bluestone JA. Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. Journal of Immunology (Baltimore, Md. : 1950). 179: 1004-12. PMID 17617592 DOI: 10.4049/Jimmunol.179.2.1004  0.433
2007 Kang SM, Tang Q, Bluestone JA. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 7: 1457-63. PMID 17511675 DOI: 10.1111/J.1600-6143.2007.01829.X  0.683
2007 Chikuma S, Bluestone JA. Expression of CTLA‐4 and FOXP3 in cis protects from lethal lymphoproliferative disease European Journal of Immunology. 37: 1285-1289. PMID 17429849 DOI: 10.1002/Eji.200737159  0.406
2007 You S, Leforban B, Garcia C, Bach J, Bluestone JA, Chatenoud L. Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment Proceedings of the National Academy of Sciences of the United States of America. 104: 6335-6340. PMID 17389382 DOI: 10.1073/Pnas.0701171104  0.536
2007 Bour-Jordan H, Bluestone JA. Sensory neurons link the nervous system and autoimmune diabetes. Cell. 127: 1097-9. PMID 17174888 DOI: 10.1016/J.Cell.2006.11.030  0.328
2007 St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J. New reagents on the horizon for immune tolerance. Annual Review of Medicine. 58: 329-46. PMID 16987079 DOI: 10.1146/Annurev.Med.58.061705.145449  0.448
2007 Tang Q, Zheng Y, Adams J, Kreuwel H, Gadkar K, Penaranda C, Shoda L, Whiting CC, Young D, Bluestone J. In Vivo and In Silico Modeling the Dynamics of Autoimmune Diabetes Clinical Immunology. 123: S70. DOI: 10.1016/J.Clim.2007.03.377  0.56
2007 Fife BT, Guleria I, Bupp M, Tang Q, Eagar T, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone J. The Programmed Death-1 (pd-1) Pathway Regulates Peripheral T Cell Tolerance During Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice Clinical Immunology. 123: S27. DOI: 10.1016/J.Clim.2007.03.248  0.762
2007 Iwai H, Kodama K, Dang D, Fathman CG, Bluestone JA. Gene Expression Analysis by Microarray Following Anti-CD3 Antibody Therapy of NOD Mice Clinical Immunology. 123: S9. DOI: 10.1016/J.Clim.2007.03.197  0.351
2006 Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. The Journal of Experimental Medicine. 203: 2737-47. PMID 17116737 DOI: 10.1084/Jem.20061577  0.75
2006 Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: Results of a blinded controlled study Diabetes. 55: 2588-2594. PMID 16936208 DOI: 10.2337/Db05-1378  0.437
2006 Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunological Reviews. 212: 217-37. PMID 16903917 DOI: 10.1111/J.0105-2896.2006.00421.X  0.711
2006 Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. The Journal of Clinical Investigation. 116: 2252-61. PMID 16886063 DOI: 10.1172/Jci27856  0.756
2006 Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. Journal of Immunology (Baltimore, Md. : 1950). 177: 1451-9. PMID 16849451 DOI: 10.4049/Jimmunol.177.3.1451  0.701
2006 Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. The Journal of Experimental Medicine. 203: 1701-11. PMID 16818678 DOI: 10.1084/Jem.20060772  0.517
2006 Tang Q, Bluestone JA. Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Nature Immunology. 7: 551-3. PMID 16715063 DOI: 10.1038/Ni0606-551  0.686
2006 Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, Von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recentonset autoimmune diabetes by inducing Tregs Journal of Clinical Investigation. 116: 1371-1381. PMID 16628253 DOI: 10.1172/Jci27191  0.455
2006 Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 24: 233-8. PMID 16546089 DOI: 10.1016/J.Immuni.2006.03.001  0.312
2006 Masteller EL, Tang Q, Bluestone JA. Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Seminars in Immunology. 18: 103-10. PMID 16458533 DOI: 10.1016/J.Smim.2006.01.004  0.7
2006 Chen W, Bluestone JA, Herold KC. Achieving antigen-specific tolerance in diabetes: regulating specifically. International Reviews of Immunology. 24: 287-305. PMID 16318983 DOI: 10.1080/08830180500379671  0.549
2006 Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nature Immunology. 7: 83-92. PMID 16311599 DOI: 10.1038/Ni1289  0.818
2006 Gross DM, Earle KE, Bluestone JA, Tang Q. Regulatory T cells and their role in type 1 diabetes Current Opinion in Endocrinology and Diabetes. 13: 319-324. DOI: 10.1097/01.Med.0000235320.23917.C5  0.666
2006 Bluestone JA, Boehmer Hv. Regulatory T cells Seminars in Immunology. 18: 77. DOI: 10.1016/J.Smim.2006.01.003  0.507
2006 Guleria I, Dada S, Eckenrode S, Bupp MG, Ansari M, Vadivel N, Trikudanathan S, Fiorina P, Khosroshahi A, Yagita H, Azuma M, Atkinson M, She J, Bluestone J, Sayegh M. Su.26. PDL1 Regulates Autoimmunity By Limiting Expansion of Autoreactive Th1 Cells and Mediates Resistance to Diabetes in Nod Mice Clinical Immunology. 119: S168. DOI: 10.1016/J.Clim.2006.04.453  0.54
2005 Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. The Journal of Experimental Medicine. 202: 1375-86. PMID 16287710 DOI: 10.1084/Jem.20050855  0.566
2005 Bour-Jordan H, Thompson HL, Bluestone JA. Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. Journal of Immunology (Baltimore, Md. : 1950). 175: 5649-55. PMID 16237054 DOI: 10.4049/Jimmunol.175.9.5649  0.406
2005 Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Current Opinion in Immunology. 17: 638-42. PMID 16209918 DOI: 10.1016/J.Coi.2005.09.002  0.744
2005 Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. The Journal of Clinical Investigation. 115: 2904-13. PMID 16167085 DOI: 10.1172/Jci23961  0.492
2005 Dai YD, Jensen KP, Lehuen A, Masteller EL, Bluestone JA, Wilson DB, Sercarz EE. A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreas. Journal of Immunology (Baltimore, Md. : 1950). 175: 3621-7. PMID 16148106 DOI: 10.4049/Jimmunol.175.6.3621  0.48
2005 Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. Journal of Immunology (Baltimore, Md. : 1950). 175: 3053-9. PMID 16116193 DOI: 10.4049/Jimmunol.175.5.3053  0.713
2005 Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity. 23: 115-26. PMID 16111631 DOI: 10.1016/J.Immuni.2005.08.002  0.476
2005 Chikuma S, Abbas AK, Bluestone JA. B7-independent inhibition of T cells by CTLA-4. Journal of Immunology (Baltimore, Md. : 1950). 175: 177-81. PMID 15972645 DOI: 10.4049/Jimmunol.175.1.177  0.493
2005 Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 54: 1763-9. PMID 15919798 DOI: 10.2337/Diabetes.54.6.1763  0.378
2005 Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, Bluestone JA. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clinical Immunology (Orlando, Fla.). 115: 3-9. PMID 15870014 DOI: 10.1016/J.Clim.2005.02.017  0.701
2005 Loser K, Scherer A, Krummen MBW, Varga G, Higuchi T, Schwarz T, Sharpe AH, Grabbe S, Bluestone JA, Beissert S. An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice Journal of Immunology. 174: 5298-5305. PMID 15843526 DOI: 10.4049/Jimmunol.174.9.5298  0.46
2005 Bezbradica JS, Stanic AK, Matsuki N, Bour-Jordan H, Bluestone JA, Thomas JW, Unutmaz D, Van Kaer L, Joyce S. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. Journal of Immunology (Baltimore, Md. : 1950). 174: 4696-705. PMID 15814694 DOI: 10.4049/Jimmunol.174.8.4696  0.465
2005 Kohm AP, Williams JS, Bickford AL, McMahon JS, Chatenoud L, Bach JF, Bluestone JA, Miller SD. Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis Journal of Immunology. 174: 4525-4534. PMID 15814673 DOI: 10.4049/Jimmunol.174.8.4525  0.539
2005 Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nature Reviews. Immunology. 5: 343-9. PMID 15775994 DOI: 10.1038/Nri1574  0.529
2005 Anderson MS, Bluestone JA. The NOD mouse: A model of immune dysregulation Annual Review of Immunology. 23: 447-485. PMID 15771578 DOI: 10.1146/Annurev.Immunol.23.021704.115643  0.409
2005 Matis L, Hedrick S, Bluestone J. To T or not to T: is it selection? Current Biology : Cb. 1: 262-4. PMID 15336139 DOI: 10.1016/0960-9822(91)90078-B  0.404
2005 Sperling AI, Bluestone JA. Non-classical MHC molecules: the first line of defence? Current Biology : Cb. 3: 294-6. PMID 15335753 DOI: 10.1016/0960-9822(93)90183-O  0.531
2004 Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. European Journal of Immunology. 34: 2996-3005. PMID 15468055 DOI: 10.1002/Eji.200425143  0.637
2004 Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. The Journal of Clinical Investigation. 114: 979-87. PMID 15467837 DOI: 10.1172/Jci20483  0.534
2004 Judkowski V, Rodriguez E, Pinilla C, Masteller E, Bluestone JA, Sarvetnick N, Wilson DB. Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. Clinical Immunology (Orlando, Fla.). 113: 29-37. PMID 15380527 DOI: 10.1016/J.Clim.2004.03.007  0.488
2004 Bluestone JA, Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 101: 14622-6. PMID 15322272 DOI: 10.1073/Pnas.0405234101  0.732
2004 Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity. 20: 757-67. PMID 15189740 DOI: 10.1016/J.Immuni.2004.05.008  0.568
2004 Eagar TN, Turley DM, Padilla J, Karandikar NJ, Tan L, Bluestone JA, Miller SD. CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance. Journal of Immunology (Baltimore, Md. : 1950). 172: 7442-50. PMID 15187122 DOI: 10.4049/Jimmunol.172.12.7442  0.493
2004 Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. The Journal of Experimental Medicine. 199: 1455-65. PMID 15184499 DOI: 10.1084/Jem.20040139  0.725
2004 Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone JA. Notch 1 signaling regulates peripheral T cell activation. Immunity. 20: 407-15. PMID 15084270 DOI: 10.1016/S1074-7613(04)00081-0  0.667
2004 Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 4: 390-401. PMID 14961992 DOI: 10.1046/J.1600-6143.2003.00351.X  0.447
2004 Stock PG, Bluestone JA. Beta-cell replacement for type I diabetes. Annual Review of Medicine. 55: 133-56. PMID 14746513 DOI: 10.1146/Annurev.Med.55.091902.103539  0.339
2004 Matthews JB, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: slow but steady progress. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 3: 794-803. PMID 12814471 DOI: 10.1046/J.1600-6135.2003.0154.X  0.368
2003 Chikuma S, Bluestone JA. CTLA-4 and tolerance: the biochemical point of view. Immunologic Research. 28: 241-253. PMID 14713717 DOI: 10.1385/Ir:28:3:241  0.516
2003 Boden E, Tang Q, Bour-Jordan H, Bluestone JA. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Foundation Symposium. 252: 55-63; discussion 63. PMID 14609212 DOI: 10.1002/0470871628.Ch5  0.712
2003 Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. Journal of Immunology (Baltimore, Md. : 1950). 171: 5587-95. PMID 14607967 DOI: 10.4049/Jimmunol.171.10.5587  0.531
2003 Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. Journal of Immunology (Baltimore, Md. : 1950). 171: 3348-52. PMID 14500627 DOI: 10.4049/Jimmunol.171.7.3348  0.676
2003 Belghith M, Bluestone JA, Barriot S, Mégret J, Bach J, Chatenoud L. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes Nature Medicine. 9: 1202-1208. PMID 12937416 DOI: 10.1038/Nm924  0.516
2003 Ding W, Beissert S, Deng L, Miranda E, Cassetty C, Seiffert K, Campton KL, Yan Z, Murphy GF, Bluestone JA, Granstein RD. Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis. The Journal of Clinical Investigation. 111: 1923-31. PMID 12813028 DOI: 10.1172/Jci15722  0.454
2003 Starwalt SE, Masteller EL, Bluestone JA, Kranz DM. Directed evolution of a single-chain class II MHC product by yeast display. Protein Engineering. 16: 147-56. PMID 12676983 DOI: 10.1093/Proeng/Gzg018  0.321
2003 Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nature Reviews. Immunology. 3: 253-7. PMID 12658273 DOI: 10.1038/Nri1032  0.536
2003 Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). The Journal of Clinical Investigation. 111: 409-18. PMID 12569167 DOI: 10.1172/Jci16090  0.486
2003 Tang Q, Smith JA, Szot GL, Zhou P, Alegre ML, Henriksen KJ, Thompson CB, Bluestone JA. CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. Journal of Immunology (Baltimore, Md. : 1950). 170: 1510-6. PMID 12538715 DOI: 10.4049/Jimmunol.170.3.1510  0.761
2003 Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity. 18: 41-51. PMID 12530974 DOI: 10.1016/S1074-7613(02)00505-8  0.389
2003 Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nature Immunology. 4: 182-8. PMID 12524538 DOI: 10.1038/Ni884  0.693
2003 Chikuma S, Imboden JB, Bluestone JA. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. The Journal of Experimental Medicine. 197: 129-35. PMID 12515820 DOI: 10.1084/Jem.20021646  0.511
2002 Finger EB, Bluestone JA. When ligand becomes receptor--tolerance via B7 signaling on DCs. Nature Immunology. 3: 1056-7. PMID 12407416 DOI: 10.1038/Ni1102-1056  0.457
2002 Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. The Journal of Rheumatology. 29: 1907-13. PMID 12233885  0.509
2002 Masteller EL, Bluestone JA. Immunotherapy of insulin-dependent diabetes mellitus. Current Opinion in Immunology. 14: 652-659. PMID 12183168 DOI: 10.1016/S0952-7915(02)00375-8  0.468
2002 Rulifson IC, Szot GL, Palmer E, Bluestone JA. Inability to induce tolerance through direct antigen presentation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2: 510-9. PMID 12118894 DOI: 10.1034/J.1600-6143.2002.20604.X  0.832
2002 Rotrosen D, Matthews JB, Bluestone JA. The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. The Journal of Allergy and Clinical Immunology. 110: 17-23. PMID 12110811 DOI: 10.1067/Mai.2002.124258  0.376
2002 Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML. Cutting edge: Targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells Journal of Immunology. 169: 633-637. PMID 12097362 DOI: 10.4049/Jimmunol.169.2.633  0.677
2002 Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. The New England Journal of Medicine. 346: 1692-8. PMID 12037148 DOI: 10.1056/Nejmoa012864  0.447
2002 Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. The Src family kinase Fyn mediates signals induced by TCR antagonists. Journal of Immunology (Baltimore, Md. : 1950). 168: 4480-7. PMID 11970992 DOI: 10.4049/Jimmunol.168.9.4480  0.691
2002 Eagar TN, Karandikar NJ, Bluestone JA, Miller SD. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. European Journal of Immunology. 32: 972-81. PMID 11920563 DOI: 10.1002/1521-4141(200204)32:4<972::Aid-Immu972>3.0.Co;2-M  0.571
2001 Szot GL, Zhou P, Rulifson I, Wang J, Guo Z, Kim O, Newell KA, Thistlethwaite JR, Bluestone JA, Alegre ML. Different Mechanisms of Cardiac Allograft Rejection in Wildtype and CD28-deficient Mice American Journal of Transplantation. 1: 38-46. PMID 12095035 DOI: 10.1034/J.1600-6143.2001.010108.X  0.841
2001 Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells--they're back and critical for regulation of autoimmunity! Immunological Reviews. 182: 149-163. PMID 11722631 DOI: 10.1034/J.1600-065X.2001.1820112.X  0.569
2001 Wells AD, Walsh MC, Bluestone JA, Turka LA. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. The Journal of Clinical Investigation. 108: 895-903. PMID 11560959 DOI: 10.1172/Jci13220  0.552
2001 Salomon B, Rhee L, Bour-Jordan H, Hsin H, Montag A, Soliven B, Arcella J, Girvin AM, Padilla J, Miller SD, Bluestone JA. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. The Journal of Experimental Medicine. 194: 677-84. PMID 11535635 DOI: 10.1084/Jem.194.5.677  0.488
2001 O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide Journal of Immunology. 167: 2555-2560. PMID 11509595 DOI: 10.4049/Jimmunol.167.5.2555  0.683
2001 Diamond B, Bluestone J, Wofsy D. The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis and Rheumatism. 44: 1730-5. PMID 11508422 DOI: 10.1002/1529-0131(200108)44:8<1730::Aid-Art307>3.0.Co;2-2  0.324
2001 Tesciuba AG, Subudhi S, Rother RP, Faas SJ, Frantz AM, Elliot D, Weinstock J, Matis LA, Bluestone JA, Sperling AI. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. Journal of Immunology (Baltimore, Md. : 1950). 167: 1996-2003. PMID 11489981 DOI: 10.4049/Jimmunol.167.4.1996  0.8
2001 Sperling AI, Bluestone JA. ICOS costimulation: It's not just for TH2 cells anymore. Nature Immunology. 2: 573-4. PMID 11429535 DOI: 10.1038/89709  0.611
2001 Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, Bluestone J, Getz GS. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 21: 1011-6. PMID 11397712 DOI: 10.1161/01.Atv.21.6.1011  0.301
2001 Wu Q, Salomon B, Chen M, Wang Y, Hoffman LM, Bluestone JA, Fu YX. Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor Journal of Experimental Medicine. 193: 1327-1332. PMID 11390440 DOI: 10.1084/Jem.193.11.1327  0.375
2001 Bluestone JA, Matthe J. The Immune Tolerance Network: tolerance at the crossroads. Philosophical Transactions of the Royal Society B. 356: 773-776. PMID 11375080 DOI: 10.1098/Rstb.2001.0847  0.389
2001 Zhou P, Szot G, Guo Z, Kim O, He G, Wang J, Grusby M, Newell K, Thistlethwaite J, Bluestone J, Alegre M. Role of STAT6 signaling in the induction and long-term maintenance of tolerance mediated by CTLA4-Ig. Transplantation Proceedings. 33: 214-6. PMID 11266784 DOI: 10.1016/S0041-1345(00)01979-5  0.533
2001 Alegre M, Fallarino F, Zhou P, Frauwirth K, Thistlethwaite J, Newell K, Gajewski T, Bluestone J. Transplantation and the CD28/CTLA4/B7 pathway Transplantation Proceedings. 33: 209-211. PMID 11266782 DOI: 10.1016/S0041-1345(00)01977-1  0.583
2001 Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation Annual Review of Immunology. 19: 225-252. PMID 11244036 DOI: 10.1146/Annurev.Immunol.19.1.225  0.565
2001 Griffin MD, Holman PO, Tang Q, Ashourian N, Korthäuer U, Kranz DM, Bluestone JA. Development and applications of surface-linked single chain antibodies against T-cell antigens. Journal of Immunological Methods. 248: 77-90. PMID 11223070 DOI: 10.1016/S0022-1759(00)00344-6  0.692
2001 Griffin MD, Bachman LA, McKean DJ, Kumar R, Bluestone JA. Manipulating the co-stimulatory properties of antigen presenting cells: A key strategy for the promotion of immunologic tolerance American Journal of Kidney Diseases. 37: A17. DOI: 10.1016/S0272-6386(01)80173-6  0.395
2000 Zhou P, Szot GL, Guo Z, Kim O, He G, Wang J, Grusby MJ, Newell KA, Thistlethwaite JR, Bluestone JA, Alegre ML. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. Journal of Immunology (Baltimore, Md. : 1950). 165: 5580-7. PMID 11067913 DOI: 10.4049/Jimmunol.165.10.5580  0.603
2000 Karandikar NJ, Eagar TN, Vanderlugt CL, Bluestone JA, Miller SD. CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 109: 173-80. PMID 10996219 DOI: 10.1016/S0165-5728(00)00322-2  0.451
2000 Bluestone JA, Matthews JB. The immune tolerance network--an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists. Clinical Immunology. 96: 171-173. PMID 10964534 DOI: 10.1006/Clim.2000.4892  0.353
2000 Neville KL, Dal Canto MC, Bluestone JA, Miller SD. CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease. Journal of Virology. 74: 8349-57. PMID 10954534 DOI: 10.1128/Jvi.74.18.8349-8357.2000  0.425
2000 Schwarz A, Beissert S, Grosse-Heitmeyer K, Gunzer M, Bluestone JA, Grabbe S, Schwarz T. Evidence for Functional Relevance of CTLA-4 in Ultraviolet-Radiation-Induced Tolerance Journal of Immunology. 165: 1824-1831. PMID 10925260 DOI: 10.4049/Jimmunol.165.4.1824  0.482
2000 Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 164: 6230-6. PMID 10843675 DOI: 10.4049/Jimmunol.164.12.6230  0.324
2000 Sciammas R, Bluestone JA. TCRgammadelta cells and viruses. Microbes and Infection. 1: 203-12. PMID 10801231 DOI: 10.1016/S1286-4579(99)80035-5  0.345
2000 Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 12: 431-440. PMID 10795741 DOI: 10.1016/S1074-7613(00)80195-8  0.494
2000 Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, Fallarino F, Collins M, Segal DM, Gajewski TF, Kranz DM, Bluestone JA. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). Journal of Immunology (Baltimore, Md. : 1950). 164: 4433-42. PMID 10779742 DOI: 10.4049/Jimmunol.164.9.4433  0.558
2000 Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cellular Immunology. 200: 16-26. PMID 10716879 DOI: 10.1006/Cimm.2000.1617  0.632
2000 Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, Miller SD. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 164: 670-8. PMID 10623809 DOI: 10.4049/Jimmunol.164.2.670  0.435
2000 Korthäuer U, Nagel W, Davis EM, Le Beau MM, Menon RS, Mitchell EO, Kozak CA, Kolanus W, Bluestone JA. Anergic T lymphocytes selectively express an integrin regulatory protein of the cytohesin family. Journal of Immunology (Baltimore, Md. : 1950). 164: 308-18. PMID 10605025 DOI: 10.4049/Jimmunol.164.1.308  0.509
2000 Girvin AM, Dal Canto MC, Rhee L, Salomon B, Sharpe A, Bluestone JA, Miller SD. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. Journal of Immunology (Baltimore, Md. : 1950). 164: 136-43. PMID 10605004 DOI: 10.4049/Jimmunol.164.1.136  0.483
2000 Guo Z, Meng L, Kim O, He G, Szot GL, Hart J, Wang J, Collins M, Thistlethwaite JR, Sharpe AH, Bluestone JA, Newell KA. DIFFERENT EFFECTS OF VARIOUS STRATEGIES FOR BLOCKING CD28/B7 INTERACTIONS ON INTESTINAL ALLOGRAFT REJECTION. Transplantation. 69: S416-S417. DOI: 10.1097/00007890-200004271-01165  0.343
2000 Szot GL, Zhou P, Wang J, Guo Z, Newell KA, Thistlethwaite JR, Bluestone JA, Alegre M. ROLE OF CD8+ T CELLS IN CARDIAC ALLOGRAFT REJECTION IN WILD-TYPE AND CD28-DEFICIENT MICE. Transplantation. 69: S413. DOI: 10.1097/00007890-200004271-01154  0.472
2000 Zhou P, Szot GL, Guo Z, He G, Wang J, Newell KA, Thistlethwaite JR, Bluestone JA, Alegre M. SIGNALING THROUGH STAT4 OR STAT6 IS NOT REQUIRED FOR ACUTE ALLOGRAFT REJECTION OR FOR THE INDUCTION OF TOLERANCE BY CTLA4-IG TREATMENT IN A MURINE CARDIAC TRANSPLANT MODEL. Transplantation. 69: S379. DOI: 10.1097/00007890-200004271-01026  0.531
2000 Rulifson IC, Szot GL, Palmer E, Bluestone JA. A CLASS II-ALLOSPECIFIC TCR CD4+ TRANSGENIC MOUSE DEMONSTRATES THAT COSTIMULATION IS NOT REQUIRED FOR THE REJECTION OF SKIN ALLOGRAFTS VIA THE DIRECT PATHWAY. Transplantation. 69: S240. DOI: 10.1097/00007890-200004271-00497  0.76
1999 Rajagopal K, Sommers CL, Decker DC, Mitchell EO, Korthauer U, Sperling AI, Kozak CA, Love PE, Bluestone JA. RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation. The Journal of Experimental Medicine. 190: 1657-68. PMID 10587356 DOI: 10.1084/Jem.190.11.1657  0.795
1999 Mathur M, Herrmann K, Qin Y, Gulmen F, Li X, Krimins R, Weinstock J, Elliott D, Bluestone JA, Padrid P. CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice. American Journal of Respiratory Cell and Molecular Biology. 21: 498-509. PMID 10502560 DOI: 10.1165/Ajrcmb.21.4.3714  0.441
1999 Punch JD, Lin J, Bluestone J, Bromberg JS. CD2 and CD3 receptor-mediated tolerance: constraints on T cell activation. Transplantation. 67: 741-748. PMID 10096532 DOI: 10.1097/00007890-199903150-00017  0.503
1999 Guehler SR, Bluestone JA, Barrett TA. Activation and peripheral expansion of murine T-cell receptor gamma delta intraepithelial lymphocytes. Gastroenterology. 116: 327-34. PMID 9922313 DOI: 10.1016/S0016-5085(99)70129-0  0.434
1999 Newell KA, He G, Guo Z, Kim O, Hart J, Collins M, Thistlethwaite JR, Bluestone JA. CTLA4IG FAILS TO PREVENT INTESTINAL ALLOGRAFT REJECTION DUE TO AN INABILITY TO INHIBIT CD8 T CELL RESPONSES Transplantation. 67: S45. DOI: 10.1097/00007890-199904150-00181  0.504
1998 Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA. Molecular Basis of T Cell Inactivation by CTLA-4 Science. 282: 2263-2266. PMID 9856951 DOI: 10.1126/Science.282.5397.2263  0.502
1998 Vanderlugt CL, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, Bluestone JA, Miller SD. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunological Reviews. 164: 63-72. PMID 9795764 DOI: 10.1111/J.1600-065X.1998.Tb01208.X  0.467
1998 Karandikar NJ, Vanderlugt CL, Bluestone JA, Miller SD. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. Journal of Neuroimmunology. 89: 10-8. PMID 9726820 DOI: 10.1016/S0165-5728(98)00058-7  0.444
1998 Padrid PA, Mathur M, Li X, Herrmann K, Qin Y, Cattamanchi A, Weinstock J, Elliott D, Sperling AI, Bluestone JA. CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma. American Journal of Respiratory Cell and Molecular Biology. 18: 453-62. PMID 9533932 DOI: 10.1165/Ajrcmb.18.4.3055  0.673
1998 Neville KL, Bluestone JA, Miller SD. Interference with costimulation alters disease course in Theiler's Murine Encephalomyelitis Virus-Induced Demyelinating Disease (TMEV-IDD) Faseb Journal. 12: A1100. DOI: 10.1016/S0165-5728(98)91533-8  0.368
1997 Vanderlugt CL, Karandikar NJ, Lenschow DJ, Dal Canto MC, Bluestone JA, Miller SD. Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE. Journal of Neuroimmunology. 79: 113-8. PMID 9394783 DOI: 10.1016/S0165-5728(97)00108-2  0.372
1997 Smith JA, Bluestone JA. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Current Opinion in Immunology. 9: 648-654. PMID 9368773 DOI: 10.1016/S0952-7915(97)80044-1  0.443
1997 Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. The Journal of Experimental Medicine. 186: 229-38. PMID 9221752 DOI: 10.1084/Jem.186.2.229  0.466
1997 Sciammas R, Kodukula P, Tang Q, Hendricks RL, Bluestone JA. T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis. The Journal of Experimental Medicine. 185: 1969-75. PMID 9166426 DOI: 10.1084/Jem.185.11.1969  0.625
1997 Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. The Journal of Experimental Medicine. 185: 1413-22. PMID 9126922 DOI: 10.1084/Jem.185.8.1413  0.423
1997 Madrenas J, Chau LA, Smith J, Bluestone JA, Germain RN. The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. The Journal of Experimental Medicine. 185: 219-29. PMID 9016871 DOI: 10.1084/Jem.185.2.219  0.352
1997 Sperling AI, Bluestone JA. The complexities of T-cell co-stimulation: CD28 and beyond. Immunological Reviews. 153: 155-82. PMID 9010723 DOI: 10.1111/J.1600-065X.1996.Tb00924.X  0.693
1997 Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA. CD28 costimulation promotes the production of Th2 cytokines. Journal of Immunology (Baltimore, Md. : 1950). 158: 658-65. PMID 8992981  0.805
1997 Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T. Enhanced Induction of Antitumor T-Cell Responses by Cytotoxic T Lymphocyte-associated Molecule-4 Blockade: The Effect Is Manifested Only at the Restricted Tumor-bearing Stages Cancer Research. 57: 4036-4041. DOI: 10.11501/3169195  0.384
1996 Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA. CD28/B7 Interactions Deliver a Unique Signal to Naive T Cells That Regulates Cell Survival but Not Early Proliferation Journal of Immunology. 157: 3909-3917. PMID 8892622  0.813
1996 Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity. 5: 285-93. PMID 8808683 DOI: 10.1016/S1074-7613(00)80323-4  0.534
1996 Lenschow DJ, Walunas TL, Bluestone JA. Cd28/B7 System Of T Cell Costimulation Annual Review of Immunology. 14: 233-258. PMID 8717514 DOI: 10.1146/Annurev.Immunol.14.1.233  0.505
1996 Bluestone JA, Khattri R, Sciammas R, Sperling AI. TCR gamma delta cells: a specialized T-cell subset in the immune system. Annual Review of Cell and Developmental Biology. 11: 307-53. PMID 8689560 DOI: 10.1146/Annurev.Cb.11.110195.001515  0.716
1996 La Motte RN, Rubin MA, Barr E, Leiden JM, Bluestone JA, Mokyr MB. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunology, Immunotherapy : Cii. 42: 161-9. PMID 8640844 DOI: 10.1007/S002620050266  0.309
1996 Woodle ES, Hussein S, Bluestone JA. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells Transplantation. 61: 798-803. PMID 8607186 DOI: 10.1097/00007890-199603150-00021  0.479
1996 Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Barrett TA, Bluestone JA, Vallera DA. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens Blood. 87: 827-837. DOI: 10.1182/Blood.V87.2.827.Bloodjournal872827  0.473
1996 Blazar BR, Taylor PA, Bluestone JA, Vallera DA. Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens Blood. 87: 4463-4472. DOI: 10.1182/Blood.V87.10.4463.Bloodjournal87104463  0.488
1995 Barrett TA, Bluestone JA. Development of TCR gamma delta iIELs. Seminars in Immunology. 7: 299-305. PMID 8580462 DOI: 10.1016/1044-5323(95)90011-X  0.411
1995 DeLuca D, Bluestone JA, Shultz LD, Sharrow SO, Tatsumi Y. Programmed differentiation of murine thymocytes during fetal thymus organ culture Journal of Immunological Methods. 178: 13-29. PMID 7829862 DOI: 10.1016/0022-1759(94)00236-P  0.512
1995 Hu Q, Davidson D, Schwartzberg PL, Macchiarini F, Lenardo MJ, Bluestone JA, Matis LA. Identification of Rlk, a novel protein tyrosine kinase with predominant expression in the T cell lineage Journal of Biological Chemistry. 270: 1928-1934. PMID 7829530 DOI: 10.1074/Jbc.270.4.1928  0.461
1995 Alegre ML, Lenschow DJ, Bluestone JA. Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors Digestive Diseases and Sciences. 40: 58-64. PMID 7821120 DOI: 10.1007/Bf02063942  0.688
1995 Sperling AI, Green JM, Mosley RL, Smith PL, DiPaolo RJ, Klein JR, Bluestone JA, Thompson CB. CD43 is a murine T cell costimulatory receptor that functions independently of CD28. The Journal of Experimental Medicine. 182: 139-46. PMID 7790813 DOI: 10.1084/Jem.182.1.139  0.724
1995 Sciammas R, Tatsumi Y, Sperling AI, Arunan K, Bluestone JA. TCR gamma delta cells: mysterious cells of the immune system. Immunologic Research. 13: 268-79. PMID 7616054 DOI: 10.1007/Bf02935618  0.67
1995 Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity. 3: 541-547. PMID 7584144 DOI: 10.1016/1074-7613(95)90125-6  0.529
1995 Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity. 2: 555-9. PMID 7540940 DOI: 10.1016/1074-7613(95)90000-4  0.506
1995 Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB. Absence of B7-dependent responses in CD28-deficient mice. Immunity. 1: 501-8. PMID 7534617 DOI: 10.1016/1074-7613(94)90092-2  0.724
1995 Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. The Journal of Experimental Medicine. 181: 1145-55. PMID 7532678 DOI: 10.1084/Jem.181.3.1145  0.409
1995 Lenschow DJ, Zeng Y, Hathcock KS, Zuckerman LA, Freeman G, Thistlethwaite JR, Gray GS, Hodes RJ, Bluestone JA. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation. 60: 1171-8. PMID 7482727 DOI: 10.1097/00007890-199511270-00019  0.476
1994 Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation Immunity. 1: 405-413. PMID 7882171 DOI: 10.1016/1074-7613(94)90071-X  0.551
1994 June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunology Today. 15: 321-31. PMID 7522010 DOI: 10.1016/0167-5699(94)90080-9  0.506
1994 Alegre M-, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 57: 1537-1543. DOI: 10.1097/00007890-199457110-00001  0.463
1994 Zeng Y, Gage A, Montag A, Rothlein R, Thistlethwaite JR, Bluestone JA. Inhibition Of Transplant Rejection By Pretreatment Of Xenogeneic Pancreatic Islet Cells With Anti-Icam-1 Antibodies Transplantation. 58: 681-689. DOI: 10.1097/00007890-199409000-00008  0.371
1994 Alegre M, Sattar HA, Herold KC, Smith J, Tepper MA, Bluestone JA. PREVENTION OF THE HUMORAL RESPONSE INDUCED BY AN ANTI-CD3 MONOCLONAL ANTIBODY BY DEOXYSPERGUALIN IN A MURINE MODEL1 Transplantation. 57: 1786-1794. DOI: 10.1097/00007890-199406270-00018  0.656
1993 Wells FB, Tatsumi Y, Bluestone JA, Hedrick SM, Allison JP, Matis LA. Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. The Journal of Experimental Medicine. 177: 1061-70. PMID 8459203 DOI: 10.1084/Jem.177.4.1061  0.406
1993 Dent AL, Matis LA, Bluestone JA, Hedrick SM. Evidence for programmed cell death of self-reactive γδ T cell receptor-positive thymocytes European Journal of Immunology. 23: 2482-2487. PMID 8405049 DOI: 10.1002/Eji.1830231016  0.435
1993 Qian D, Sperling AI, Lancki DW, Tatsumi Y, Barrett TA, Bluestone JA, Fitch FW. The gamma chain of the high-affinity receptor for IgE is a major functional subunit of the T-cell antigen receptor complex in gamma delta T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 90: 11875-9. PMID 8265641 DOI: 10.1073/Pnas.90.24.11875  0.693
1993 Sydora BC, Mixter PF, Houlden B, Hershberg R, Levy R, Comay M, Bluestone J, Kronenberg M. T-Cell Receptor γδ Diversity and Specificity of Intestinal Intraepithelial Lymphocytes: Analysis of IEL-Derived Hybridomas Cellular Immunology. 152: 305-322. PMID 8258140 DOI: 10.1006/Cimm.1993.1293  0.377
1993 Lenschow DJ, Bluestone JA. T cell co-stimulation and in vivo tolerance Current Opinion in Immunology. 5: 747-752. PMID 7694594 DOI: 10.1016/0952-7915(93)90132-C  0.558
1993 Lenschow DJ, Su GH, Zuckerman LA, Nabavi N, Jellis CL, Gray GS, Miller J, Bluestone JA. Expression and functional significance of an additional ligand for CTLA-4. Proceedings of the National Academy of Sciences of the United States of America. 90: 11054-8. PMID 7504292 DOI: 10.1073/Pnas.90.23.11054  0.487
1992 Barrett TA, Delvy ML, Kennedy DM, Lefrancois L, Matis LA, Dent AL, Hedrick SM, Bluestone JA. Mechanism of self-tolerance of gamma/delta T cells in epithelial tissue. The Journal of Experimental Medicine. 175: 65-70. PMID 1730927 DOI: 10.1084/Jem.175.1.65  0.451
1992 Lenschow D, Zeng Y, Thistlethwaite, Montag A, Brady W, Gibson M, Linsley P, Bluestone J. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg Science. 257: 789-792. PMID 1323143 DOI: 10.1126/Science.1323143  0.512
1992 Hiruma K, Hirsch R, Patchen M, Bluestone JA, Gress RE. Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space. Blood. 79: 3050-3058. DOI: 10.1182/Blood.V79.11.3050.Bloodjournal79113050  0.518
1992 Lehman TJ, Spencer CH, Hirsch R, Bluestone J. F(ab')2 fragments of monoclonal antibodies to CD3 block, but whole antibodies enhance lactobacillus casei cell wall-induced coronary arteritis in mice Progress in Pediatric Cardiology. 1: 71. DOI: 10.1016/S1058-9813(06)80025-1  0.353
1991 Evavold BD, Yokoyama A, Hirsch R, Bluestone JA, Quintans J. T helper 2 (Th2) but not Th1 clones co-stimulate resting T cells in the presence of anti-CD3 monoclonal antibody. International Immunology. 1: 443-9. PMID 2535137 DOI: 10.1093/Intimm/1.4.443  0.552
1991 Shimada S, Caughman SW, Bluestone JA, Cron RQ, Owen FL, Smith JA, Katz SI. Freshly isolated Thy-1+ dendritic epidermal cells express T cell receptor gamma delta-CD3. Journal of Dermatological Science. 1: 459-64. PMID 1981147 DOI: 10.1016/0923-1811(90)90017-8  0.468
1991 Woodle ES, Thistlethwaite JR, Ghobrial IA, Jolliffe LK, Stuart FP, Bluestone JA. OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation. 52: 354-360. PMID 1908148 DOI: 10.1097/00007890-199108000-00033  0.419
1991 Newell KA, Ellenhorn JDI, Bruce DS, Bluestone JA. In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor Proceedings of the National Academy of Sciences of the United States of America. 88: 1074-1078. PMID 1899481 DOI: 10.1073/Pnas.88.3.1074  0.443
1991 Barrett TA, Hedrick SM, Dent AL, Delvy ML, Kennedy DM, Matis LA, Bluestone JA. Control of self-reactivity in the intestine. Immunologic Research. 10: 341-8. PMID 1835488 DOI: 10.1007/Bf02919719  0.346
1991 Ferran C, Dy M, Sheehan K, Schreiber R, Grau G, Bluestone J, Bach J‐, Chatenoud L. Cascade modulation by anti‐tumor necrosis factor monoclonal antibody of interferon‐γ, interleukin 3 and interleukin 6 release after triggering of the CD33/T cell receptor activation pathway European Journal of Immunology. 21: 2349-2353. PMID 1833202 DOI: 10.1002/Eji.1830211009  0.4
1991 Lefrancois L, LeCorre R, Mayo J, Bluestone JA, Goodman T. Selection of Vδ+ T cell receptors of intestinal intraepithelial lymphocytes is dependent on Class II histocompatibility antigen expression Current Topics in Microbiology and Immunology. 173: 255-267. PMID 1833152 DOI: 10.1007/978-3-642-76492-9_36  0.452
1991 Kakkanaiah VN, Nagarkatti M, Bluestone JA, Nagarkatti PS. CD4-CD8- thymocytes from MRL-lpr/lpr mice exhibit abnormal proportions of alpha beta- and gamma delta-TCR+ cells and demonstrate defective responsiveness when activated through the TCR. Cellular Immunology. 137: 269-82. PMID 1832583 DOI: 10.1016/0008-8749(91)90078-P  0.448
1991 Wells FB, Gahm SJ, Hedrick SM, Bluestone JA, Dent A, Matis LA. Requirement for positive selection of gamma delta receptor-bearing T cells. Science (New York, N.Y.). 253: 903-5. PMID 1831565 DOI: 10.1126/Science.1831565  0.428
1991 Newell KA, Ellenhorn JDI, Hirsch R, Bluestone JA. Immunopotentiation of anti-viral and anti-tumor immune responses using anti-T cell receptor antibodies and mitogens Annals of the New York Academy of Sciences. 636: 279-287. PMID 1793214 DOI: 10.1111/J.1749-6632.1991.Tb33458.X  0.519
1991 Ferran C, Dy M, Sheehan K, Merite S, Schreiber R, Landais P, Grau G, Bluestone J, Bach J-, Chatenoud L. Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release. Clinical and Experimental Immunology. 86: 537-543. PMID 1721015 DOI: 10.1111/J.1365-2249.1991.Tb02966.X  0.381
1991 Bluestone JA, Cron RQ, Barrett TA, Houlden B, Sperling AI, Dent A, Hedrick S, Rellahan B, Matis LA. Repertoire development and ligand specificity of murine TCR gamma delta cells. Immunological Reviews. 120: 5-33. PMID 1650760 DOI: 10.1111/J.1600-065X.1991.Tb00585.X  0.634
1991 Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. Transplantation. 52: 361-368. DOI: 10.1097/00007890-199108000-00034  0.439
1991 Bluestone JA, Hirsch R, Eckhaus M, Nettleman D, Richards J, Geller RB. Anti-CD3 therapy enhances hematopoiesis and blocks graft-versus-host disease The International Journal of Cell Cloning. 9: 91-104. DOI: 10.1002/Stem.5530090712  0.468
1990 Cron RQ, Coligan JE, Bluestone JA. Polymorphisms and diversity of T-cell receptor-gamma proteins expressed in mouse spleen. Immunogenetics. 31: 220-8. PMID 2329007 DOI: 10.1007/Bf00204891  0.319
1990 Grusby MJ, Nabavi N, Wong H, Dick RF, Bluestone JA, Schotz MC, Glimcher LH. Cloning of an interleukin-4 inducible gene from cytotoxic T lymphocytes and its identification as a lipase Cell. 60: 451-459. PMID 2302735 DOI: 10.1016/0092-8674(90)90596-7  0.366
1990 Lefrancois L, LeCorre R, Mayo J, Bluestone JA, Goodman T. Extrathymic selection of TCR γδ+ T cells by class II major histocompatibility complex molecules Cell. 63: 333-340. PMID 2208290 DOI: 10.1016/0092-8674(90)90166-C  0.411
1990 Ellenhorn JDI, Woodle ES, Ghobreal I, Thistlethwaite JR, Bluestone JA. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation. 50: 608-612. PMID 2145669 DOI: 10.1097/00007890-199010000-00016  0.528
1990 Hirsch R, Bluestone JA, Denenno L, Gress RE. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation. 49: 1117-1123. PMID 2141740 DOI: 10.1097/00007890-199006000-00018  0.427
1990 Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel L, Grau G, Bluestone J, Bach J, Chatenoud L. Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation European Journal of Immunology. 20: 509-515. PMID 2138557 DOI: 10.1002/Eji.1830200308  0.396
1990 Dent AL, Matis LA, Hooshmand F, Widacki SM, Bluestone JA, Hedrick SM. Self-reactive gamma delta T cells are eliminated in the thymus. Nature. 343: 714-9. PMID 1968227 DOI: 10.1038/343714A0  0.524
1989 Houlden BA, Matis LA, Cron RQ, Widacki SM, Brown GD, Pampeno C, Meruelo D, Bluestone JA. A TCRγδ cell recognizing a novel TL-encoded gene product Cold Spring Harbor Symposia On Quantitative Biology. 54: 45-55. PMID 2576978 DOI: 10.1101/Sqb.1989.054.01.006  0.309
1989 Hirsch R, Chatenoud L, Gress RE, Sachs DH, Bach J, Bluestone JA. Suppression of the humoral response to anti-CD3 monoclonal antibody. Transplantation. 47: 853-856. PMID 2524123 DOI: 10.1097/00007890-198905000-00021  0.388
1989 Bluestone JA, Potter T. T cell clones and monoclonal antibodies: immunologic probes of major histocompatibility complex class I molecules Chemical Immunology. 46: 23-48. PMID 2514705 DOI: 10.1159/000318822  0.395
1989 Potter TA, Rajan TV, Dick RF, Bluestone JA. Substitution at residue 227 of H-2 class I molecules abrogates recognition by CD8-dependent, but not CD8-independent, cytotoxic T lymphocytes. Nature. 337: 73-5. PMID 2462676 DOI: 10.1038/337073A0  0.472
1988 Ajitkumar P, Geier SS, Kesari KV, Borriello F, Nakagawa M, Bluestone JA, Saper MA, Wiley DC, Nathenson SG. Evidence that multiple residues on both the α-helices of the class I MHC molecule are simultaneously recognized by the T cell receptor Cell. 54: 47-56. PMID 3260136 DOI: 10.1016/0092-8674(88)90178-X  0.336
1988 Langlet C, Guimezanes A, Kaldy P, Boyer C, Buferne M, Poenie M, Tsien R, Leo O, Bluestone J, Leserman L. Role of Ti/CD3, Thy-1, and Ly-6 in cytolytic T-cell activation analyzed with Ti loss variants. Annals of the New York Academy of Sciences. 532: 33-43. PMID 2902820 DOI: 10.1111/J.1749-6632.1988.Tb36323.X  0.496
1988 Ellenhorn JD, Hirsch R, Schreiber H, Bluestone JA. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science (New York, N.Y.). 242: 569-71. PMID 2902689 DOI: 10.1126/Science.2902689  0.42
1987 Matis LA, Cron R, Bluestone JA. Major histocompatibility complex-linked specificity of gamma delta receptor-bearing T lymphocytes. Nature. 330: 262-4. PMID 3499575 DOI: 10.1038/330262A0  0.509
1987 Pardoll DM, Lew AM, Maloy WL, Fowlkes BJ, Kruisbeek A, Bluestone JA, Schwartz RH, Coligan JE. Analysis of T-cell receptor gamma chain expression in the thymus Advances in Experimental Medicine and Biology. 225: 241-246. PMID 3453602 DOI: 10.1007/978-1-4684-5442-0_21  0.456
1987 Yokoyama WM, Koning F, Stingl G, Bluestone JA, Coligan JE, Shevach EM. Production of a T cell hybridoma that expresses the T cell receptor gamma/delta heterodimer. The Journal of Experimental Medicine. 165: 1725-30. PMID 3108449 DOI: 10.1084/Jem.165.6.1725  0.462
1987 Bluestone JA, Pardoll D, Sharrow SO, Fowlkes BJ. Characterization of murine thymocytes with CDS-associated T-cell receptor structures Nature. 326: 82-84. PMID 3102972 DOI: 10.1038/326082A0  0.518
1987 Pardoll DM, Fowlkes BJ, Bluestone JA, Kruisbeek A, Maloy WL, Coligan JE, Schwartz RH. Differential expression of two distinct T-cell receptors during thymocyte development Nature. 326: 79-81. PMID 3102971 DOI: 10.1038/326079A0  0.492
1987 Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide Proceedings of the National Academy of Sciences of the United States of America. 84: 1374-1378. PMID 2950524 DOI: 10.1073/Pnas.84.5.1374  0.493
1987 Stingl G, Koning F, Yamada H, Yokoyama WM, Tschachler E, Bluestone JA, Steiner G, Samelson LE, Lew AM, Coligan JE. Thy-1+ dendritic epidermal cells express T3 antigen and the T-cell receptor gamma chain. Proceedings of the National Academy of Sciences of the United States of America. 84: 4586-90. PMID 2885839 DOI: 10.1073/Pnas.84.13.4586  0.459
1987 Bluestone JA, Pescovitz MD, Frels WI, Singer DS, Hodes RJ. Cytotoxic T lymphocyte recognition of a xenogeneic major histocompatibility complex antigen expressed in transgenic mice. European Journal of Immunology. 17: 1035-1041. PMID 2440691 DOI: 10.1002/Eji.1830170721  0.39
1986 Lew AM, Pardoll DM, Maloy WL, Fowlkes BJ, Kruisbeek A, Cheng SF, Germain RN, Bluestone JA, Schwartz RH, Coligan JE. Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes Science. 234: 1401-1405. PMID 3787252 DOI: 10.1126/Science.3787252  0.451
1986 Bluestone JA, Leo O, Epstein SL, Sachs DH. Idiotypic manipulation of the immune response to transplantation antigens. Immunological Reviews. 90: 5-28. PMID 3516865 DOI: 10.1111/J.1600-065X.1986.Tb01475.X  0.312
1986 Nakagawa M, Zeff RA, Geier SS, Bluestone JA, Nathenson SG. Somatic cell variants of H-2Kb: a point mutation in the first extracellular domain results in altered immune recognition. Immunogenetics. 24: 381-5. PMID 3491786 DOI: 10.1007/Bf00377956  0.333
1986 Lynch DH, Cole BC, Bluestone JA, Hodes RJ. Cross-reactive recognition by antigen-specific, major histocompatibility complex-restricted T cells of a mitogen derived from Mycoplasma arthritidis is clonally expressed and I-E restricted European Journal of Immunology. 16: 747-751. PMID 3487458 DOI: 10.1002/Eji.1830160706  0.456
1986 Shinohara N, Bluestone JA, Sachs DH. Cloned cytotoxic T lymphocytes that recognize an I-A region product in the context of a class I antigen. Journal of Experimental Medicine. 163: 972-980. PMID 3485175 DOI: 10.1084/Jem.163.4.972  0.342
1986 Ildstad ST, Bluestone JA, Sachs DH. Alloresistance to engraftment of allogeneic donor bone marrow is mediated by an Lyt-2+ T cell in mixed allogeneic reconstitution (C57BL/10Sn + B10.D2/nSn → C57BL/10Sn) Journal of Experimental Medicine. 163: 1343-1348. PMID 2939173 DOI: 10.1084/Jem.163.5.1343  0.325
1985 Rabinowitz R, Bluestone JA, Sachs DH. Evidence for a regulatory idiotypic network in the in vivo response to H-2 antigens. Journal of Experimental Medicine. 162: 745-755. PMID 3894563 DOI: 10.1084/Jem.162.2.745  0.327
1985 Frels WI, Bluestone JA, Hodes RJ, Capecchi MR, Singer DS. Expression of a microinjected porcine class I major histocompatibility complex gene in transgenic mice. Science (New York, N.Y.). 228: 577-80. PMID 3885396 DOI: 10.1126/Science.3885396  0.313
1985 Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 316: 354-6. PMID 3160953 DOI: 10.1038/316354A0  0.493
1985 Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance Journal of Experimental Medicine. 162: 231-244. PMID 3159825 DOI: 10.1084/Jem.162.1.231  0.332
1985 Bluestone JA, Foo M, Allen H, Segal D, Flavell RA. Allospecific cytolytic T lymphocytes recognize conformational determinants on hybrid mouse transplantation antigens. The Journal of Experimental Medicine. 162: 268-81. PMID 2409207 DOI: 10.1084/Jem.162.1.268  0.314
1983 Bluestone JA, Hodes RJ. Cell-surface molecules involved in T-cell functions Immunology Today. 4: 256-259. PMID 25290304 DOI: 10.1016/0167-5699(83)90045-2  0.49
1983 Auchincloss H, Bluestone JA, Sachs DH. Antiidiotypes against anti-H-2 monoclonal antibodies. V. In vivo antiidiotype treatment induces idiotype-specific helper T cells. The Journal of Experimental Medicine. 157: 1273-86. PMID 6220109 DOI: 10.1084/Jem.157.4.1273  0.519
1981 Epstein SL, Ozato K, Bluestone JA, Sachs DH. Idiotypes of anti-Ia antibodies. I. Expression of the 14-4-4S idiotype in humoral immune responses Journal of Experimental Medicine. 154: 397-410. PMID 6790657 DOI: 10.1084/Jem.154.2.397  0.311
Show low-probability matches.